Since the widespread use of anti‐VEGF to treat patients with nAMD, the number of blind registrations due to AMD has dramatically fallen.[10] However, despite the advances in anti‐VEGF treatments, nAMD remains one of the most common causes of blindness in the world.[11]. This evidence concerns the gene VEGFA and blindness (disorder).